2
项与 Anti-BAFFR CART(Tianjin Medical University General Hospital) 相关的临床试验 / Not yet recruiting临床1/2期IIT Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
This is an open-label, single-arm, dose-escalation study in up to 20 participants with relapsed/refractory Neuromyelitis Optica Spectrum Disorders (NMOSD). The aim is to evaluate the safety and efficacy of the treatment with BAFFR CART.
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen receptor (CAR)-targeted B-cell activating factor receptor (BAFFR) in refractory neuroimmune diseases. The study design is divided into two parts, the first of which will be given to each patient at 3 incremental dose levels to establish the maximum tolerated dose (MTD). Each disease is expected to enroll 12 patients who meet the inclusion criteria. In the second part, 15 patients per disease will be recruited to further characterize the efficacy of the MTD.
100 项与 Anti-BAFFR CART(Tianjin Medical University General Hospital) 相关的临床结果
100 项与 Anti-BAFFR CART(Tianjin Medical University General Hospital) 相关的转化医学
100 项与 Anti-BAFFR CART(Tianjin Medical University General Hospital) 相关的专利(医药)
100 项与 Anti-BAFFR CART(Tianjin Medical University General Hospital) 相关的药物交易